An observational study in Urinary Tract Infections, sponsored by University of Southampton. Recruiting at 1 site in United Kingdom. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-31.
Sponsored by University of Southampton · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Urinary Tract Infections with a site in United Kingdom — 7 open to participants now, 10 under way, none of them phase 3. Urinary Tract Infections · United Kingdom.
Among the 31 studies in Urinary Tract Infections with a site in United Kingdom, this one is the 14th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2023, is one of 14 observational ones, and was the 25th registered.
808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.
Browse Urinary Tract Infections studies →7 of the 31 studies in Urinary Tract Infections with a site in United Kingdom are open now. Recruiting first, the newest first:
Queen's University, Belfast · Sites in United Kingdom
University College, London · Sites in United Kingdom
Ages 18+ · Women only
Royal Free Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Infectopharm Arzneimittel GmbH · Sites in United Kingdom, Austria, Germany and 2 more countries
Ages 18+
University Hospitals of North Midlands NHS Trust · Sites in United Kingdom
Ages 18+ · Women only
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 241 across 199 observational studies indexed under Urinary Tract Infections.
Median enrollment 48 across the 17 interventional studies, 1,250 across the 14 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 31 have an industry lead sponsor. The 10 most frequent:
University of Southampton is the lead sponsor of 123 studies on the registry; 18 are open to participants now.
University of Southampton has 1 study filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in Urinary Tract Infections with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06824129QIAGEN Gaithersburg, IncClinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR | 2026-12 |
| NCT07698041Katherine FinlayRUTISS-Diary and RUTISS-65 Study | 2027-06-30 |
| NCT06710899University Hospitals of North Midlands NHS TrustVitamin C and Hiprex in rUTI | 2027-08 |
| NCT07202949University College, LondonA Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Urinary Tract Infections with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The number of care home residents is increasing and urinary tract infections (UTIs) are common amongst this group. Accurate diagnosis of UTI is important because not treating an infection may lead to serious consequences including death. However, giving antibiotic treatment when there isn't an infection causes side effects and antibiotic resistance, making future infections harder to treat.
Unfortunately, there are several challenges that mean that it is difficult to diagnose UTI accurately in care home residents. Firstly, UTIs don't always cause clear symptoms for people who live in care homes. They sometimes just cause symptoms like confusion which can have lots of different possible causes. Secondly, it may be hard for people living with dementia to say how they are feeling or to easily provide a urine sample. Thirdly, many people who live in care homes have bacteria present in their urine even when they are well, but this not harmful and does not need treatment. Finally, urine tests that are currently available do not give accurate or quick results.
We have thought about some new ways that might help show us if someone in a care home really has a UTI but we don't know yet whether these will work. Our ideas include 1) Working out which symptoms or signs mean a UTI is more likely 2) Detecting new markers of infection in urine samples and 3) Trying out new bedside tests that give rapid results.
For this study we plan to recruit 100 care home residents who will be followed up over 6 months. All 100 participants will provide information and a urine sample at the beginning of the study. 25 of these participants will also provide repeated weekly samples for 4 weeks to look at any changes in the urine over time. Additional information and urine samples will be collected if a participant develops a possible UTI during the study and any treatments will be recorded.
Our findings will be used to develop a funding application for a larger study aiming to improve the diagnosis of UTI in care home residents.
This feasibility observational study will be conducted in four overlapping stages: recruiting a cohort of 100 care home residents (CHR) from up to 10 care homes across the Thames Valley and Wessex (Stage 1); collecting weekly repeated baseline urine samples from a subset of participants (without suspected UTI) (Stage 2); following all 100 participants for 6 months and collecting additional data on those who develop possible UTI (Stage 3), and interviewing participants, their families and care home staff about study feasibility and acceptability (Stage 4).
Stage 1 - Cohort recruitment and baseline data collection
Baseline assessments:
Following consent, baseline data will be collected including demographics, medical history, and a description of baseline functional ability. We will also collect a urine sample for baseline microbiological and urinary biomarker analyses for each participant.
Stage 2 - Repeat urine sampling cohort 25 CHR recruited in Stage 1 will be asked to provide weekly urine samples for four weeks. Urine samples will be sent for microbiological and urinary biomarker analyses.
CHR who develop a possible UTI during this stage will contribute to Stage 3 and will continue to have any remaining weekly samples collected if possible.
Stage 3 - Possible UTI episodes All 100 CHR recruited during Stage 1 will be followed for 6 months. Care home staff will be asked to alert the research team as soon as any participant in the cohort develops possible UTI. This would include any situation where care home staff have decided to consult with a healthcare professional because they have detected a change in the CHR or their urine and believe that a UTI is 'a likely cause'. This would not include residents who become acutely unwell from a source that is clearly not UTI at onset (e.g. chest or skin infection or cerebrovascular event).
Participants who experience possible UTI will have a 'symptomatic baseline' assessment and follow up visits at 14 and 28 days. A urine sample will be collected. If possible and this doesn't delay care, this will be before any treatment is initiated. Repeat urine samples will be collected at days 14 and 28.
Some of the urine taken at symptomatic baseline and day 28 will also be tested using one or more novel POCTs by a member of the research team.
Stage 4 - Qualitative sub-study We will conduct a qualitative evaluation to explore study acceptability and barriers and facilitators to study procedures. Care home staff, residents, and their families will be asked to participate in semi-structured interviews towards the end of the study period.
We aim to recruit a cohort of 100 care home residents over 65 years of age from up to 10 care home sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 care home residents will be recruited and followed up for 6 months.
Diagnostic Test: Candidate POCTs for detecting UTI
POCT performance will be evaluated in participants who experience possible UTI.
As a feasibility study, there is no primary outcome measure.
Time frame: Baseline
Proportion of care homes agreeing to participate when recruiting care homes as research sites.
Time frame: Baseline
Proportion of residents screened that are eligible and proportion of eligible that are recruited.
Time frame: Baseline
Proportion of baseline urine samples obtained from participants recruited (consented)
Time frame: Baseline
Proportion of repeated urine samples obtained of those participating in Stage 2
Time frame: 2, 3 and 4 weeks
Quality of urine samples obtained
Proportions of samples collected mid-stream clean catch, vs other collection techniques Proportions of samples contaminated (as reported by staff collecting samples) Proportions of samples with microbiological evidence of contamination
Time frame: Through study completion, 6 months
Adherence to urine transport protocols
Time from sampling until receipt in laboratory Proportion recorded as stored refrigerated prior to transportation
Time frame: Through study completion, 6 months
Proportion of residents that experience a possible UTI during the follow-up period that are reported to the research team.
Time frame: Through study completion, 6 months
Proportion of residents with possible UTI that are not reported to the research team.
Time frame: Assessed weekly through to study completion at 6 months
Proportion of residents with possible UTI in whom the following is obtained:
* Symptomatic baseline data on the characteristics of the possible UTI * A urine sample at onset of possible UTI * A urine sample prior to any antibiotic administration * Follow-up data * Follow-up urine samples at 14 and 28 days from symptom onset
Time frame: Through study completion, 6 months
Using semi-structured interviews with qualitative analysis to describe the views of care home staff, participants and family members on:
1. Barriers and facilitators to taking part in the study. 2. Experience of obtaining/giving consent. 3. Experience of being a participant/family member of a participant. 4. Experience of giving/collecting urine samples including resident and staff willingness and capacity to obtain weekly urine samples. 5. Experience of reporting a possible UTI to the study team and any barriers or facilitators to reporting in a timely fashion. 6. The diagnosis of UTI and how this is determined in usual care 7. The diagnosis of UTI and how this was determined during the study 8. Additional tests including POCTs for UTI
Time frame: Through study completion, 6 months
Participant baseline demographic characteristics predictive of subsequent possible UTI/clinical outcomes
Time frame: Through study completion, 6 months
Participant clinical characteristics at point of possible UTI and association with clinical outcomes
Time frame: Through study completion, 6 months
Changes in weekly sample microbiology
Description of any changes in the microbiological results of samples sent weekly from weeks 1-4
Time frame: Baseline, 2, 3 and 4 weeks
Predictors of weekly sample microbiology and changes in microbiology
Including previous urine culture results, resident demographic characteristics, and sampling characteristics
Time frame: Baseline, 2, 3 and 4 weeks
Association between asymptomatic bacteriuria at baseline or in weekly sampling and onset of possible UTI during follow up period
Time frame: Through study completion, 6 months
Association of each urinary biomarker with asymptomatic bacteriuria
Assess whether concentration of biomarkers listed below is associated with asymptomatic bacteriuria: Matrix metallopeptidase-9, neutrophil gelatinase associated lipocalin (NGAL), Interleukin , Interleukin 8, Interleukin 6, Interleukin 6, Interleukin 10, secretory IgA, and chemokine (C-X-C motif) ligand 1
Time frame: Baseline
Urinary biomarker concentrations in urine samples from asymptomatic participants without bacteriuria
Matrix metallopeptidase-9, neutrophil gelatinase associated lipocalin (NGAL), Interleukin , Interleukin 8, Interleukin 6, Interleukin 6, Interleukin 10, secretory IgA, and chemokine (C-X-C motif) ligand 1
Time frame: Baseline
Urinary biomarker concentrations in urine samples from possible UTI episodes
Matrix metallopeptidase-9, neutrophil gelatinase associated lipocalin (NGAL), Interleukin , Interleukin 8, Interleukin 6, Interleukin 6, Interleukin 10, secretory IgA, and chemokine (C-X-C motif) ligand 1
Time frame: Through study completion, 6 months
Failure rate of the POCT in residents with possible UTI (no result or invalid result)
Time frame: Through study completion, 6 months
Agreement between POCT result and laboratory enhanced culture result at symptom onset for each possible UTI episode, and at 28 days post symptom on set
Comparison to be made between each POCT result and the result from the enhanced culture carried out in the laboratory at symptomatic baseline and 28 day follow up of each possible UTI episode.
Time frame: Through study completion, 6 months
Plan to share: No — There is no plan to share IPD at this stage.
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Dec 2024, 15 months after the start.
Of 72 non-industry observational studies under Urinary Tract Infections, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 15 months is below that.
Counting every sponsor, half of 84 studies reached it within 26 months; a quarter within 11 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.